Gilead beats product hopping claims ahead of trial

A California federal court has thrown out product-hopping claims against Gilead Sciences relating to one of its HIV treatments, although the drugmaker and several others failed to escape allegations they agreed anticompetitive non-competes and pay-for-delay schemes.

Unlock unlimited access to all Global Competition Review content